TY - JOUR
T1 - Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation
AU - Oda, Naohiro
AU - Miyahara, X. Nobuaki
AU - Taniguchi, Akihiko
AU - Morichika, Daisuke
AU - Senoo, Satoru
AU - Fujii, Utako
AU - Itano, Junko
AU - Gion, Yuka
AU - Kiura, Katsuyuki
AU - Kanehiro, Arihiko
AU - Maeda, Yoshinobu
N1 - Funding Information:
This work was supported in part by Novartis Pharma Research grant (to N. Miyahara) and Daiichi-Sankyo Research Grant A17-1612 (to N. Miyahara).
Publisher Copyright:
© 2019 the American Physiological Society.
PY - 2019/3
Y1 - 2019/3
N2 - Neuro-peptide Y (NPY) is a neurotransmitter that is widely expressed in the brain and peripheral nervous system. Various immune cells express the NPY Y 1 receptor. NPY modulates these cells via its Y 1 receptor; however, involvement of NPY in the pathophysiology of bronchial asthma, particularly airway hyperresponsiveness (AHR), has not been defined. NPY-deficient and wild-type mice were intranasally sensitized and challenged to house dust mite (HDM) extract, and airway responses were monitored. After sensitization and challenge, NPY-deficient mice showed significantly lower AHR than wild-type mice, and numbers of eosinophils and levels of type 2 cytokines [interleukin (IL)-4, IL-5, and IL-13] in bronchoalveolar lavage fluid were significantly lower. Type 2 cytokine production from splenic mononuclear cells of HDM-sensitized mice was also significantly lower in NPY-deficient mice. Flow cytometry analysis showed that the number of CD4 T cells and CD11c + antigen–presenting cells (APCs) was significantly lower in the lungs of NPY-deficient mice than in wild-type mice following sensitization and challenge. Significantly fewer CD11c + APCs phagocytosed HDM in the mediastinal lymph nodes of NPY-deficient mice than in those of wild-type mice. Treatment with BIBO-3304, a NPY receptor antagonist, significantly suppressed development of HDM-induced AHR and inflammation in wild-type mice. These data identify an important contribution of NPY to allergen-induced AHR and inflammation through accumulation of dendritic cells in the airway and promotion of the type 2 immune response. Thus, manipulating NPY represents a novel therapeutic target to control allergic airway responses.
AB - Neuro-peptide Y (NPY) is a neurotransmitter that is widely expressed in the brain and peripheral nervous system. Various immune cells express the NPY Y 1 receptor. NPY modulates these cells via its Y 1 receptor; however, involvement of NPY in the pathophysiology of bronchial asthma, particularly airway hyperresponsiveness (AHR), has not been defined. NPY-deficient and wild-type mice were intranasally sensitized and challenged to house dust mite (HDM) extract, and airway responses were monitored. After sensitization and challenge, NPY-deficient mice showed significantly lower AHR than wild-type mice, and numbers of eosinophils and levels of type 2 cytokines [interleukin (IL)-4, IL-5, and IL-13] in bronchoalveolar lavage fluid were significantly lower. Type 2 cytokine production from splenic mononuclear cells of HDM-sensitized mice was also significantly lower in NPY-deficient mice. Flow cytometry analysis showed that the number of CD4 T cells and CD11c + antigen–presenting cells (APCs) was significantly lower in the lungs of NPY-deficient mice than in wild-type mice following sensitization and challenge. Significantly fewer CD11c + APCs phagocytosed HDM in the mediastinal lymph nodes of NPY-deficient mice than in those of wild-type mice. Treatment with BIBO-3304, a NPY receptor antagonist, significantly suppressed development of HDM-induced AHR and inflammation in wild-type mice. These data identify an important contribution of NPY to allergen-induced AHR and inflammation through accumulation of dendritic cells in the airway and promotion of the type 2 immune response. Thus, manipulating NPY represents a novel therapeutic target to control allergic airway responses.
KW - Airway hyperresponsiveness
KW - Allergic airway inflammation
KW - Asthma
KW - NPY
KW - Y receptor antagonist
UR - http://www.scopus.com/inward/record.url?scp=85061489819&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061489819&partnerID=8YFLogxK
U2 - 10.1152/ajplung.00386.2018
DO - 10.1152/ajplung.00386.2018
M3 - Article
C2 - 30604629
AN - SCOPUS:85061489819
SN - 1040-0605
VL - 316
SP - L407-L417
JO - American Journal of Physiology - Lung Cellular and Molecular Physiology
JF - American Journal of Physiology - Lung Cellular and Molecular Physiology
IS - 3
ER -